We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

QIAGEN,Biotype Diagnostics Form Partnership

QIAGEN,Biotype Diagnostics Form Partnership

QIAGEN,Biotype Diagnostics Form Partnership

QIAGEN,Biotype Diagnostics Form Partnership

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "QIAGEN,Biotype Diagnostics Form Partnership"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

QIAGEN and Biotype Diagnostics GmbH today announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation").

The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s proprietary ModaPlex platform, which enables customers to detect, characterize and measure up to 100 parameters simultaneously in a cost-effective and rapid manner.

The diagnostic assays developed by the Biotype Innovation are expected to add to the assay menu of the ModaPlex platform especially in the market for companion diagnostics, which are used to guide drug treatments. 

“We are very pleased to join forces with Biotype. This partnership enables us to expand the menu of our unique ModaPlex platform, offer assay development services for pharma companies and thereby expand our leadership in companion diagnostics,” said Peer Schatz, CEO of QIAGEN. “As a long-standing partner with an unparalleled expertise in molecular analysis, Biotype is the natural partner for us.” 

QIAGEN will contribute technology and access to its global commercialization engine to the joint venture, while Biotype Diagnostics GmbH will contribute know-how, assay development resources, and its scientific network. QIAGEN will have worldwide distribution rights for the assays, while Biotype Diagnostics will have co-distribution rights for Germany, Austria and Switzerland.

The partnership, structured as a joint venture, will have its head office based in Hellerau, Dresden, in newly refurbished facilities on the Campus of the Biotype Diagnostics GmbH. “The proximity will allow both companies to leverage synergies and share facilities where necessary”, says Dr. Wilhelm Zörgiebel, CEO of Biotype Diagnostics.